Page last updated: 2024-10-20

thymine and Local Neoplasm Recurrence

thymine has been researched along with Local Neoplasm Recurrence in 18 studies

Research Excerpts

ExcerptRelevanceReference
"Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)."8.12Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022)
"This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age."7.91Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019)
"Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)."7.88Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018)
"TAS-102 (trifluridine-tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal cancer."5.34TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. ( Krogh, M; Möller, S; Petersen, LN; Pfeiffer, P; Poulsen, LØ; Qvortrup, C; Thomsen, KG; Winther, SB; Yilmaz, M; Zitnjak, D, 2020)
"For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival."4.12Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022)
"Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC)."4.12Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. ( Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A, 2022)
"Trifluridine/tipiracil (TAS-102) is an important chemotherapeutic agent recommended by the Japanese guidelines as third- or fourth-line treatment for colorectal cancer."4.02[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab]. ( Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A, 2021)
"Trifluridine/tipiracil (FTD/TPI) improves the overall survival (OS) of metastatic colorectal cancer (mCRC) patients."3.96Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. ( Hata, T; Kagawa, Y; Kato, T; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2020)
"This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age."3.91Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019)
"Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC)."3.88Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. ( Ikeda, Y; Iwai, M; Kawachi, S; Kimura, M; Mitsuoka, M; Usami, E; Yasue, F; Yoshimura, T, 2018)
"The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated."3.85Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer ( Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2017)
" Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95."1.43Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.56)29.6817
2010's9 (50.00)24.3611
2020's8 (44.44)2.80

Authors

AuthorsStudies
Jalali, A1
Gard, G1
Banks, S1
Dunn, C1
Wong, HL1
Wong, R1
Lee, M1
Gately, L1
Loft, M1
Shapiro, JD1
Kosmider, S1
Tie, J1
Ananda, S1
Yeung, JM1
Jennens, R1
Lee, B1
McKendrick, J1
Lim, L1
Khattak, A1
Gibbs, P1
Oshima, K1
Hirano, H1
Shoji, H1
Iwasa, S1
Okita, N1
Takashima, A1
Boku, N1
Pfeiffer, P1
Yilmaz, M1
Möller, S1
Zitnjak, D1
Krogh, M1
Petersen, LN1
Poulsen, LØ1
Winther, SB1
Thomsen, KG1
Qvortrup, C1
Nose, Y1
Kagawa, Y1
Hata, T1
Mori, R1
Kawai, K1
Naito, A2
Sakamoto, T1
Murakami, K1
Katsura, Y1
Ohmura, Y1
Masuzawa, T1
Takeno, A1
Takeda, Y1
Kato, T2
Murata, K1
Hamada, S1
Komatsu, S1
Shibata, R1
Konishi, T1
Matsubara, D1
Soga, K1
Shimomura, K1
Ikeda, J1
Taniguchi, F1
Shioaki, Y1
Iwamoto, K1
Ohtsuka, M1
Imasato, M1
Inui, M1
Zenitani, S1
Wada, R1
Nakahara, Y1
Mikamori, M1
Furukawa, K1
Moon, J1
Asaoka, T1
Kishi, K1
Akamatsu, H1
Maeda, F1
Gan, S1
Yamada, A1
Kajiyama, D1
Tokitou, F1
Kawaguchi, M1
Amagasa, H1
Motoyama, K1
Ganno, H1
Imai, K1
Ami, K1
Iida, S1
Fukuda, A1
Ando, M1
Okano, Y1
Taniguchi, H1
Nakamura, Y1
Kotani, D1
Yukami, H1
Mishima, S1
Sawada, K1
Shirasu, H1
Ebi, H1
Yamanaka, T1
Aleshin, A1
Billings, PR1
Rabinowitz, M1
Oki, E1
Takemasa, I1
Mori, M1
Yoshino, T1
Kimura, M4
Usami, E4
Iwai, M3
Teramachi, H3
Yoshimura, T4
Arnold, D1
Prager, GW1
Quintela, A1
Stein, A1
Moreno Vera, S1
Mounedji, N1
Taieb, J1
Yasue, F1
Kawachi, S1
Mitsuoka, M1
Ikeda, Y1
Goldberg, R1
Go, M1
Ito, D1
Asano, H1
Saito, T1
Mitomi, H1
Izumi, H1
Suehara, Y1
Okubo, T1
Torigoe, T1
Takagi, T1
Kaneko, K1
Sato, K1
Matsumoto, T1
Yao, T1
Eshghyar, N1
Nikbin, B1
Amirzargar, A1
Dehghani Nazhvani, A1
Shakiba, Y1
Kämmerer, PW1
Koch, FP1
Schiegnitz, E1
Kumar, VV1
Berres, M1
Toyoshima, T1
Al-Nawas, B1
Brieger, J1
Vashist, YK1
Blessmann, M1
Trump, F1
Kalinin, V1
Kutup, A1
Schneider, C1
Gawad, K1
Kaifi, JT1
Schmelzle, R1
Izbicki, JR1
Yekebas, EF1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981]Phase 2136 participants (Anticipated)Interventional2020-09-28Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for thymine and Local Neoplasm Recurrence

ArticleYear
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4

    Topics: Colorectal Neoplasms; Disease Progression; Drug Combinations; Drugs, Investigational; Humans; Neopla

2018

Trials

2 trials available for thymine and Local Neoplasm Recurrence

ArticleYear
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
    The Lancet. Oncology, 2020, Volume: 21, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combin

2020
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Cancer science, 2021, Volume: 112, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Circulating Tu

2021

Other Studies

15 other studies available for thymine and Local Neoplasm Recurrence

ArticleYear
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
    Current problems in cancer, 2022, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms;

2022
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
    PloS one, 2022, Volume: 17, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm

2022
Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
    Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec

2020
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neo

2020
[Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations

2020
[Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations

2021
Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer
    Die Pharmazie, 2017, Jan-10, Volume: 72, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2017
Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
    Die Pharmazie, 2018, 03-05, Volume: 73, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Creatinine; Drug Combinations; Female; Humans;

2018
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
    Anticancer research, 2019, Volume: 39, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co

2019
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop

2016
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
    Die Pharmazie, 2016, Volume: 71, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female;

2016
A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up.
    Human pathology, 2011, Volume: 42, Issue:5

    Topics: Adenocarcinoma; Arthrography; Base Sequence; Cell Transformation, Neoplastic; Cysteine; Femur; Fibro

2011
Gene polymorphism of interleukin-1 alpha and beta in keratocystic odontogenic tumors.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2012, Volume: 41, Issue:9

    Topics: Adolescent; Adult; Aged; Alleles; Case-Control Studies; Child; Cytosine; Epithelial Cells; Female; F

2012
Associations between single-nucleotide polymorphisms of the VEGF gene and long-term prognosis of oral squamous cell carcinoma.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2013, Volume: 42, Issue:5

    Topics: Adenosine; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cytosine; Disease-Free Survival

2013
Microsatellite GTn-repeat polymorphism in the promoter of heme oxygenase-1 gene is an independent predictor of tumor recurrence in male oral squamous cell carcinoma patients.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2008, Volume: 37, Issue:8

    Topics: Alleles; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Forecasting; Ge

2008